Sphingosine

Sphingosine

SCHEMBL1161567

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO.CCCCCOP(=O)(O)O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.73
S1PR4 O95977 2/20 0.73
S1PR3 Q99500 2/20 0.73
S1PR5 Q9H228 2/20 0.73
ALDH1A1 P00352 2/20 0.73
S1PR2 O95136 1/20 0.73
TSPO P30536 1/20 0.73
TMEM97 Q5BJF2 1/20 0.73
SIGMAR1 Q99720 1/20 0.73
MEN1 O00255 4/20 0.70
KMT2A Q03164 4/20 0.70
MAPT P10636 3/20 0.70
GMNN O75496 2/20 0.70
LMNA P02545 2/20 0.70
GLA P06280 2/20 0.70
POLB P06746 2/20 0.70
THRB P10828 2/20 0.70
CETP P11597 2/20 0.70
MAPK1 P28482 2/20 0.70
CXCR5 P32302 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sphingosine SCHEMBL28104811 0.93 S1PR1 (0.70) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL5826051 0.91 S1PR1 (0.74) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL27759087 0.90 MEN1 (0.69) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL195430 0.89 MEN1 (0.67) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL31018980 0.88 SPHK2 (0.85) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL320150 0.88 SPHK2 (0.85) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL4779279 0.88 SPHK2 (0.85) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL21439824 0.88 SPHK2 (0.85) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL16188315 0.88 SPHK2 (0.85) S1PR1S1PR4S1PR3S1PR5ALDH1A1
Sphingosine SCHEMBL19137 0.88 SPHK2 (0.85) S1PR1S1PR4S1PR3S1PR5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190209592-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN MA INC. 2019-07-11 US disclosed
US-10166250-B2 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN MA INC. (US) 2019-01-01 US disclosed
EP-2879673-B1 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders BIOGEN MA INC (US) 2018-07-25 EP disclosed
US-20180133233-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN MA INC. 2018-05-17 US disclosed
CN-105330576-B The phosphate analogs of aryl bicyclic sphingol 1 比奥根MA公司 2018-04-10 CN disclosed
US-9827258-B2 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN MA INC. (US) 2017-11-28 US disclosed
US-20170239280-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN MA INC. 2017-08-24 US disclosed
US-9572824-B2 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN MA INC. (US) 2017-02-21 US disclosed
US-20160129023-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. 2016-05-12 US disclosed
CN-105330576-A Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN IDEC INC 2016-02-17 CN disclosed
EP-2461683-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS Biogen Idec MA Inc. (US) 2012-06-13 EP disclosed
EP-2461683-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS Biogen Idec MA Inc. (US) 2012-06-13 EP disclosed
EP-2364088-A4 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC INC (US) 2012-05-30 EP disclosed
EP-2364088-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS Biogen Idec MA Inc. (US) 2011-09-14 EP disclosed
EP-2364088-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS Biogen Idec MA Inc. (US) 2011-09-14 EP disclosed
WO-2011017561-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2011-02-10 WO disclosed
WO-2011017561-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2011-02-10 WO disclosed
US-20100160258-A1 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN IDEC MA INC. (US) 2010-06-24 US disclosed
WO-2010051030-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2010-05-06 WO disclosed
WO-2010051030-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160258-A1 Bicyclic aryl sphingosine 1-phosphate analogs S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR4 3/4885S1PR3 2/4885
US-20160129023-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR4 3/4885S1PR3 2/4885
US-20170239280-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR4 3/4885S1PR3 2/4885
US-20180133233-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR4 3/4885S1PR3 2/4885
US-10166250-B2 Bicyclic aryl sphingosine 1-phosphate analogs S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR4 3/4885S1PR3 2/4885
US-20190209592-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR4 3/4885S1PR3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.